I've read the p.r. I've relistened to the Conf Call and I'm getting conflicting info.
On the Conf Call they said 45% of SFP and 54% of placebo were removed from the trial due to hemoglobin out of acceptable range, that equals about half (150) subjects were removed.
I've seen others here post that 208 were removed.
Can somebody give me what they know to be the correct number of subjects who went to completion in the trial and how many were removed. Please tell me where you get the numbers.
300 patient study... 150 in each group. Therefore 81 people in placebo and about 67 in SFP for around 148 total seems logical to me 208 is fabricated and has no merit based on the CC